Shaker Spotlight

 

KINDEVA APPOINTS BROK WEICHBRODT AS CHIEF TRANSFORMATION OFFICER
Kindeva, a global drug delivery Contract Development and Manufacturing Organization (CDMO), has appointed Brok Weichbrodt as Chief Transformation Officer to strengthen operational excellence, scale execution, and accelerate growth. With over 20 years of experience in the pharmaceutical and biotech sector, Brok has led large- scale transformation, built high-performing teams, and delivered complex operational programs. In this role, Brok will define and lead Kindeva’s transformation roadmap, aligning strategy with execution in supply chain, procurement, engineering, EHS, and ESG across all business units. He will ensure Kindeva continues to scale effectively in a highly regulated environment, while delivering consistent, high-quality outcomes for customers and patients.

“Brok brings a proven track record of leading enterprise transformation and translating strategy into measurable results,” said David Stevens, CEO at Kindeva. “His experience across operations, quality, and complex program delivery will be critical as we strengthen our global network, improve reliability, and scale the business.”

 

Delphia Therapeutics, Inc. appoints David P. Kerstein, MD, as Chief Medical Officer
Delphia Therapeutics, Inc., a biopharmaceutical company pioneering an innovative new area of cancer biology—activation lethality—which targets cancer’s surprising vulnerability to oncogene overactivation, has appointed David P. Kerstein, MD as Chief Medical Officer. Dr. Kerstein brings significant experience in oncology drug development across early- and late-stage precision oncology programs. Dr. Kerstein most recently served as Chief Medical Officer of IDRx, a clinical-stage precision oncology company, before its acquisition by GSK in 2025. Prior to joining IDRx, Dr. Kerstein was Chief Medical Officer of Theseus Pharmaceuticals, Inc.

“David is an accomplished physician-scientist and biotechnology leader with a strong track record of advancing innovative precision oncology therapies through clinical development,” said Kevin Marks, PhD, Co-founder, President, and CEO of Delphia. “As we continue to advance activation lethality as a novel therapeutic approach, David’s leadership will be instrumental in shaping our clinical strategy and accelerating the development of potentially transformative therapies for patients with cancer.”

 

Mover Alert

 

Amgen
Former Senior VP of Amgen, Sean Bruich has taken over the role of Chief Technology Officer following Dr. David Reese’s retirement from a two decade-long career with the company. Bruich has built a career advancing technical innovation in global insights and AI organizations through pivotal moments of industry transformation. Prior to joining Amgen, Bruich was VP of Global Insights, Data Science, and Analytics at Nike.

DemeRx, Inc.
DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, has appointed Michael Snitkovsky as COO. With more than 20 years of experience advancing therapies from preclinical research through clinical development, Snitkovsky is recognized for his strategic leadership, operational rigor, and ability to unite cross‑functional and global teams around shared scientific and business objectives. His experience spans operational and program leadership, Chemistry, Manufacturing, and Controls (CMC) strategy, and more.

EVERSANA INTOUCH
EVERSANA INTOUCH, a leading global provider of commercial services to the life sciences industry, announced industry veteran Mike Guarino has been appointed CEO. He will lead strategy and operations across the agency’s core and specialty capabilities, guiding teams who work closely with clients to deliver modern, insightdriven marketing strategies. Mike brings deep experience in the agency world, with senior leadership roles across prominent healthcare and marketing organizations like IPG Health.

Flora Health
Flora Health has elevated Jolean Sheffield from CEO to COO. In her expanded role, Jolean will help scale Flora Health’s operating model as the company continues to support pharma brands and partners across EHR, point of care, access, and data-driven engagement. Her experience spans clinical care delivery, EHR implementation, physician informatics, and more. Before joining Flora Health, she worked for Baylor Scott & White Health, QliqSoft, and HIA Technologies.

ImageneBio, Inc.
ImageneBio, Inc. has brought on Matt Robbins—an experienced life sciences attorney with more than 15 years of corporate, securities, and transactional experience—as General Counsel. Robbins will oversee Imagene’s legal, corporate governance, intellectual property, and compliance functions, and provide strategic counsel. Most recently, Robbins served as General Counsel of Bright Peak Therapeutics, Inc., and before that, he spent nearly nine years at Cooley LLP in San Diego.

Real Chemistry
Real Chemistry has appointed Jessica Spano as Executive Director, Communications Strategy. Prior to joining Real Chemistry, she served as Director of Corporate Communications & PR at Omnicom Health and previously held communications leadership roles at IPG Health. In her new role, Jessica is responsible for helping shape and advance Real Chemistry’s corporate communications strategy. Her expertise includes corporate reputation, executive visibility, events, media relations, and integrated communications strategy.

Novartis
Donna Hunt, former PM360 editorial board member, has joined Novartis as Vice President and General Manager, Breast and Women’s Cancers. Coming from Johnson & Johnson, she previously served as Vice President of Sales, Marketing, and Operations, CAR-T; Director of Marketing, Sales, and Operations Retina Gene Therapies; Director of New Product Development, M&A, and more throughout her over decade-long career with the company.

PrescriberPoint
PrescriberPoint, an AI point-of-care platform, has appointed Steven Strongwater, MD as Chief Medical Officer. Dr. Strongwater will guide the Company’s clinical strategy and foster relationships with healthcare organizations. He brings more than two decades of health-system leadership, most recently serving as President and CEO of Atrius Health. He has served in executive leadership roles at major academic and integrated health systems, including UMass Medical Center, the University of Connecticut Health Center, Geisinger Health System, and Stony Brook University Hospital.

ProFound Therapeutics
ProFound Therapeutics, a Flagship Pioneering company harnessing the expanded human proteome to develop first-in-class medicines, has appointed Ainslie Little, PhD as COO. With a background spanning corporate strategy, operations, and intellectual property, Little has a track record of building enterprise capabilities, advancing platform innovation, and forming strategic partnerships. She will oversee daily operations and lead the planning and execution of strategic initiatives.

Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, has appointed Thomas McCauley, PhD as Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R&D teams and translating early scientific discoveries into clinical programs. He will be responsible for leading Stoke’s scientific strategy and leveraging the company’s proprietary RNA medicines platform.